Compounds > n-succinimidyl 4-iodobenzoate
Page last updated: 2024-11-08

n-succinimidyl 4-iodobenzoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-succinimidyl 4-iodobenzoate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID170152
SCHEMBL ID317627
MeSH IDM0172592

Synonyms (23)

Synonym
n-succinimidyl-4-iodobenzoate
n-succinimidyl 4-iodobenzoate
39028-25-6
(2,5-dioxopyrrolidin-1-yl) 4-iodobenzoate
ns-p-ib
2,5-pyrrolidinedione, 1-((4-iodobenzoyl)oxy)-
2,5-dioxopyrrolidin-1-yl 4-iodobenzoate
SCHEMBL317627
AKOS024257918
n-succinimidyl4-iodobenzoate
FT-0698366
c11h8ino4
2,5-pyrrolidinedione, 1-[(4-iodobenzoyl)oxy]-
DTXSID20192294
GS-5649
mfcd24387072
n-succinimidyl p-iodobenzoate
F11342
FUJICALGSOMFAM-UHFFFAOYSA-N
CS-0060245
2,5-dioxopyrrolidin-1-yl4-iodobenzoate
2,5-dioxo-1-pyrrolidinyl 4-iodobenzoate
SY122378
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pentetic acid
Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.		210pentacarboxylic acidcopper chelator
n-succinimidyl 3-iodobenzoate
[no description available]		1.9710
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		210
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0110